"We have incorporated Symbio Pharmaceuticals in the spirit of addressing underserved therapeutic areas in Japan, and other Asia-Pacific Rim countries including China, Korea, Taiwan and Singapore, particularly in cancer, hematology and autoimmune disease. Our guiding principle is to deliver drugs to patients in dire need by tapping the global resource of drug candidates as embodied in the role of a 'conductor,' orchestrating the performance of key instruments and players in the drug industry in order to expedite the availability of life-saving therapies for Japanese physicians and patients."

Representative Director
President & CEO
Fuminori Yoshida